What are the clinical applications of quinolone antibiotics?🙌🙌🙌

1. Introduction.

Quinolones have a broad antibacterial spectrum. They are more effective
against Gram-negative bacteria than Gram-positive bacteria. Commonly used quinolone drugs include: ① Ciprofloxacin has the strongest activity against Gram-negative bacteria, especially Pseudomonas aeruginosa. ② Levofloxacin has good activity against most Gram-positive and Gram-negative bacteria. ③ Moxifloxacin has broad-spectrum antibacterial activity, with strong activity against Gram-positive bacteria, anaerobes, Mycobacterium tuberculosis, Legionella, Mycoplasma, and Chlamydia. Levofloxacin and moxifloxacin have bioavailability exceeding 90%. They can be administered sequentially via intravenous and oral administration. They have long half-lives and are generally given once daily. Ciprofloxacin has low oral bioavailability. It has a short half-life and is generally given twice daily or three times daily. Levofloxacin and ciprofloxacin are primarily excreted through the kidneys, so dosage adjustments are necessary for patients with renal insufficiency. Some quinolones (such as gemifloxacin, gatifloxacin, levofloxacin, and moxifloxacin) have high concentrations in lung tissue and exhibit good bactericidal activity against common pathogens in lung tissue. They demonstrate good antibacterial activity and pharmacokinetics in the treatment of community-acquired respiratory infections. Quinolone drugs all share the common structure of pyridoxine. Early quinolone drugs did not contain a fluorine atom in their structure. Later, a fluorine atom was introduced at the 6-position of the quinolone nucleus to enhance its inhibitory effect on DNA gyrase and its penetration into cells, thereby strengthening its antibacterial activity. Therefore, they can be divided into non-fluoroquinolones and fluoroquinolones. Common fluoroquinolones include ciprofloxacin, levofloxacin, and moxifloxacin.

2. Pharmacokinetics.

Fluoroquinolones are well absorbed orally. The oral bioavailability of most fluoroquinolones is close to or greater than 90%. Food generally does not affect the absorption of fluoroquinolones, but it can delay the time to peak absorption. Foods rich in calcium, iron, and magnesium can reduce the bioavailability of the drugs. Fluoroquinolones have a large distribution volume, mostly around 100 L, which is significantly larger than that of aminoglycosides or β-lactam antibiotics. Therefore, fluoroquinolones are widely distributed in tissues and body fluids. Drug concentrations in the lungs, kidneys, prostate, urine, bile, feces, macrophages, and neutrophils are higher than in the blood, but concentrations in cerebrospinal fluid, bone tissue, and prostatic fluid are lower. The drug can also be distributed to the lacrimal glands, salivary glands, genitourinary system, and respiratory mucosa. Drug elimination pathways differ. Pefloxacin is primarily metabolized in the liver and excreted via bile. Ofloxacin, levofloxacin, lomefloxacin, and gatifloxacin are excreted unchanged (over 80%) via the kidneys. For other drugs, both hepatic and renal elimination are equally important. 

3. Antibacterial properties.

Fluoroquinolones are bactericidal drugs. Their bactericidal concentration is 2 to 4 times the microinhibitory concentration (MIC). Third and fourth generation quinolones are broad-spectrum bactericides. Later-developed drugs such as moxifloxacin and gatifloxacin, in addition to retaining good antibacterial activity against Gram-negative bacteria, further enhanced their killing effects on Gram-positive bacteria, Mycobacterium tuberculosis, Legionella, Mycoplasma, and Chlamydia, especially improving their antibacterial activity against anaerobic bacteria such as Bacteroides fragilis, Fusobacterium spp., Peptostreptococcus spp., and anaerobic spore-forming Clostridium spp. Ciprofloxacin still has the strongest killing effect against Pseudomonas aeruginosa.

4. Mechanism of action.

Quinolone drugs target DNA gyrase and topoisomerase IV. They interfere with bacterial chromosome replication and transcription by binding to these enzymes. At low concentrations, they disrupt DNA replication, and at high concentrations, they cause cell death, thus exerting their antibacterial effect. The mechanisms of quinolone drug resistance are multifactorial. These include target site variations caused by chromosomal mutations, decreased bacterial outer membrane permeability or increased drug efflux leading to reduced drug uptake, and overexpression of repair enzymes and target site protective proteins.

5. Clinical applications.

1. Genitourinary tract infections: Ciprofloxacin and ofloxacin are recommended for treating uncomplicated gonococcal urethritis or cervicitis. Escherichia coli generally has a high quinolone resistance rate, therefore, for complicated urinary tract infections, drug sensitivity results should be used as a reference. Ciprofloxacin is the first-line drug for Pseudomonas aeruginosa urethritis.

2. Respiratory system infections: Taking upper respiratory tract infections as an example, moxifloxacin and levofloxacin can be used as empirical treatment options.

3. Intestinal infections and typhoid fever: Quinolones are the first-line empirical treatment.

4. Bone, joint and soft tissue infections: Bone and joint infections can be treated with rifampin in combination with ciprofloxacin and levofloxacin, depending on drug sensitivity results. For skin and soft tissue infections, such as diabetic foot ulcers with a diameter >2 cm or depth involving the fascia, quinolones in combination with other drugs can be used.

5. Other: It can be used as a second-line treatment option for tuberculosis, brucellosis, cholera, etc.

6. Precautions.

Quinolones are not suitable for routine use in children. Quinolones should be avoided in patients under the age of 18. 

Quinolone drugs may cause photosensitivity of the skin (avoid sun exposure during medication), joint lesions, tendinitis, tendon rupture (including various routes of administration, some of which may occur after discontinuation of the drug), and occasionally cause QT interval prolongation on electrocardiogram.

Drugs containing metal ions such as calcium, aluminum, and magnesium, as well as antacids, can chelate with most quinolone drugs when used together, affecting the absorption of quinolone drugs and significantly reducing their bioavailability and blood concentration. Therefore, the timing of medication administration should be staggered according to the specific drugs being used.

Read More

Precautions regarding novel oral anticoagulants.📃📃📃

Atrial fibrillation is a common persistent arrhythmia. It can significantly increase the risk of stroke. Novel oral anticoagulants (NOACs) are widely used in clinical practice for atrial fibrillation anticoagulation due to their superior safety and ease of administration. The four commonly used NOACs are dabigatran, which directly inhibits thrombin, and rivaroxaban, apixaban and edoxaban, which inhibit factor Xa.

Pharmacokinetics of NOACs and the Effect of Antiarrhythmic Drugs (AADs) on Their Anticoagulant Effect.

The selection of NOACs should consider factors such as bioavailability, potential drug interactions along metabolic pathways, elimination half-life, and the presence of antagonists. In the absence of clear indications, reducing or increasing the dose will increase adverse events without increasing safety. Different NOACs have different metabolic characteristics. When used in combination with antiarrhythmic drugs (AADs), attention should be paid to the effect of AADs on NOAC blood concentrations, and appropriate drug selection and dosage adjustments should be made.

**White indicates no drug interactions. Gray indicates no data. Yellow indicates use with caution. Orange indicates low dose (Dabigatran) or reduced dose (Edoxaban). Red indicates contraindication, as it is not recommended due to increased blood drug concentration.

What is the NOAC dosage?

Improper use of NOAC dosage may have adverse consequences for patients with atrial fibrillation. Off-label use of low-dose NOACs increases the risk of stroke. Off-label use of higher-dose NOACs increases the risk of major bleeding. Therefore, correct use of NOACs and minimizing adverse outcomes in patients with atrial fibrillation are crucial.

How to choose between NOACs and warfarin for elderly patients with atrial fibrillation?

For elderly patients with atrial fibrillation, NOAC anticoagulation therapy is preferred. It recommends anticoagulation therapy with dabigatran etexilate, rivaroxaban, or edoxaban. If warfarin is used, the INR should be maintained at 2.0–3.0 or 1.6–2.5 (for patients ≥ 75 years of age or those at high risk of bleeding with a HASBLED score ≥ 3).

Management of Anticoagulation-Related Bleeding:

1. Minor bleeding related to NOACs: Discontinue medication for 12–24 hours if necessary.

2. Moderate to severe bleeding: Consider using blood products, hemodialysis, etc., depending on the anticoagulant used.

3. Life-threatening bleeding: Use specific antagonists (vitamin K, edasuzumab, or andexanet-α, etc.).

Whether or when to resume anticoagulation therapy after bleeding requires careful consideration of the patient's thrombotic and bleeding risks.

Switching between anticoagulants: Switching between different anticoagulants should follow the principle of not affecting the effectiveness of anticoagulation therapy and minimizing the risk of bleeding.

Read More

Is it more appropriate to take metformin before or after meals?😐😐😐

Metformin has a significant hypoglycemic effect. It does not increase the risk of hypoglycemia when used alone. It also has good tolerability and safety, and its price is relatively inexpensive. Therefore, it remains a widely used oral hypoglycemic agent in clinical practice.

The hypoglycemic pharmacological effects of metformin.

1. Inhibition of hepatic glycogen output

Blood glucose is produced in the liver through gluconeogenesis (the conversion of non-carbohydrate substances into glucose). Metformin can reduce hepatic gluconeogenesis, thereby lowering fasting blood glucose levels.

2. Improve insulin sensitivity

Metformin activates adenosine monophosphate-activated protein kinase (AMPK) in fat and muscle cells. This promotes glucose uptake and utilization, thereby lowering postprandial blood glucose levels.

3. Increase glucagon-like peptide-1 (GLP-1) levels

GLP-1 can stimulate insulin secretion, delay gastric emptying, and reduce glucose absorption. Metformin, on the other hand, can promote GLP-1 secretion by acting directly on intestinal L cells or by regulating gut microbiota.

**Metformin is a potent oral hypoglycemic agent. As a monotherapy, it can reduce glycated hemoglobin (HbA1c) by 1% to 1.5%.

Other effects of metformin besides lowering blood sugar

1. Anti-cancer

People with type II diabetes are more likely to develop breast cancer, endometrial cancer, colorectal cancer, and other cancers. Clinical studies have found that metformin can be used to prevent breast and endometrial cancer in obese individuals. It also can reduce the risk of colorectal polyps developing into colorectal cancer. Metformin can also increase the sensitivity of tumors to chemotherapy drugs.

2. Improve Polycystic Ovary Syndrome (PCOS)

PCOS has a high prevalence among women of reproductive age. Its main manifestations include excessive androgens (acne, hirsutism), menstrual disorders, ovulation disorders, and polycystic ovarian changes. PCOS is also often accompanied by obesity and insulin resistance. Metformin can correct hyperandrogenemia by lowering blood insulin levels. This improves ovarian ovulation and enhances the effectiveness of ovulation induction treatment.

3. The preventive effect of diabetes

Prediabetes includes impaired fasting glucose (≥6.1 to <7.0 mmol/L) and impaired glucose tolerance (2-hour post-glucose load blood glucose ≥7.8 to <11.1 mmol/L). Clinical studies have shown that metformin can effectively reduce the risk of developing type II diabetes in people with prediabetes. In addition, metformin also has potential cardiovascular protective effects.

Dosage of metformin tablets

The minimum recommended dose is 500 mg/day. The optimal effective dose is 2000 mg/day. The maximum dose is 2550 mg/day. Metformin should be started at a low dose and gradually increased to reduce gastrointestinal reactions (such as diarrhea and nausea). Take 2 to 3 times daily, with or immediately after meals. Taking metformin after meals will slow down the absorption rate and reduce the extent of absorption, but it can reduce gastrointestinal reactions.

Dosage of metformin extended-release tablets

The maximum dose of metformin extended-release tablets is 2000 mg/day. Compared with regular tablets, extended-release tablets may have better gastrointestinal tolerability and improve patient medication adherence. Take once daily with dinner. Sustained-release tablets must be swallowed whole; do not crush or chew them. Taking on an empty stomach will reduce absorption by approximately 30%. Take once daily with dinner. Sustained-release tablets must be swallowed whole; do not crush or chew them. Taking on an empty stomach will reduce absorption by approximately 30%.

Dosage of Metformin enteric-coated tablets

The usual daily dose is 1 to 1.5g, with a maximum daily dose not exceeding 2g. Take 2 to 3 times daily, half an hour before meals. The coating of enteric-coated tablets needs to dissolve in the alkaline environment of the intestines. Taking it before meals allows the tablet to quickly enter the intestines, reducing stomach discomfort.

Regularly monitor vitamin B12 levels

Long-term use of metformin can cause vitamin B12 deficiency in patients. Therefore, it is recommended that patients with insufficient vitamin B12 intake or absorption have their vitamin B12 levels monitored annually before starting metformin treatment and after treatment. If deficiency is found, appropriate supplementation should be given, especially for patients with anemia and peripheral neuropathy.

Read More